Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Corbus Pharmaceuticals Holdings Inc Stock Research

CRBP

6.80USD+0.30(+4.62%)Market Closed
Watchlist

Market Summary

USD6.80+0.30
Market Closed
4.62%

CRBP Stock Price

CRBP RSI Chart

CRBP Valuation

Market Cap

30.1M

Price/Earnings (Trailing)

-0.65

Price/Free Cashflow

-0.8

CRBP Price/Sales (Trailing)

CRBP Profitability

Return on Equity

-307.76%

Return on Assets

-98.08%

Free Cashflow Yield

-125.07%

CRBP Fundamentals

CRBP Revenue

CRBP Earnings

Earnings (TTM)

-46.2M

Earnings Y/Y

33.7%

Earnings Q/Q

50.5%

Price Action

52 Week Range

0.1013.17
(Low)(High)

Last 7 days

-3.1%

Last 30 days

1.7%

Last 90 days

-22.6%

Trailing 12 Months

3677.8%

CRBP Financial Health

Current Ratio

3.19

Debt/Equity

0.64

Debt/Cashflow

-1.77

CRBP Investor Care

Shares Dilution (1Y)

6.05%

Diluted EPS (TTM)

-6.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CRBP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-10
Cohen Yuval
bought
1,003
0.264
3,800
chief executive officer
2022-08-10
Millian Craig Stuart
bought
1,272
0.2545
5,000
chief operating officer
2022-08-10
Moran Sean F.
bought
5,198
0.2599
20,000
chief financial officer
2022-05-16
Cohen Yuval
bought
2,625
0.25
10,500
chief executive officer
2022-05-16
Moran Sean F.
bought
3,600
0.3
12,000
chief financial officer
2022-03-10
Millian Craig Stuart
bought
3,700
0.37
10,000
chief operating officer
2022-03-10
Moran Sean F.
bought
5,550
0.37
15,000
chief financial officer
2022-03-09
Cohen Yuval
bought
3,182
0.37
8,600
chief executive officer
2020-12-21
Moran Sean F.
acquired
122,500
1.4
87,500
chief financial officer
2020-12-21
Moran Sean F.
sold
-153,125
1.75
-87,500
chief financial officer

1–10 of 38

Which funds bought or sold CRBP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-30.65
-616
1,826
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
1.27
52.00
627
-%
2023-08-15
Belpointe Asset Management LLC
sold off
-100
-160
-
-%
2023-08-14
VANGUARD GROUP INC
added
-
102,293
1,406,940
-%
2023-08-14
Royal Bank of Canada
new
-
12,000
12,000
-%
2023-08-14
Sio Capital Management, LLC
unchanged
-
85,500
1,176,000
0.30%
2023-08-14
Tower Research Capital LLC (TRC)
reduced
-72.52
-2,848
1,152
-%
2023-08-14
BOOTHBAY FUND MANAGEMENT, LLC
unchanged
-
21,646
297,732
0.01%
2023-08-14
NewEdge Advisors, LLC
unchanged
-
5.00
63.00
-%
2023-08-14
IFP Advisors, Inc
added
100
24.00
34.00
-%

1–10 of 42

Latest Funds Activity

Are funds buying CRBP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRBP
No. of Funds

Schedule 13G FIlings of Corbus Pharmaceuticals Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 24, 2022
etf managers group, llc
4.95%
6,194,679
SC 13G/A
Feb 14, 2022
etf managers group, llc
8.78%
10,995,143
SC 13G/A
Jun 01, 2021
etf managers group, llc
11.39%
14,240,357
SC 13G/A
May 11, 2021
etf managers group, llc
5.34%
6,673,458
SC 13G/A
Apr 12, 2021
blackrock inc.
4.5%
5,673,664
SC 13G/A
Mar 17, 2021
etf managers group, llc
4.80%
5,997,343
SC 13G/A
Feb 16, 2021
etf managers group, llc
6.96%
5,851,347
SC 13G/A
Feb 12, 2021
etf managers group, llc
9.28%
7,796,166
SC 13G/A
Jan 29, 2021
blackrock inc.
6.2%
5,220,525
SC 13G/A
Jan 11, 2021
state street corp
1.59%
1,333,546
SC 13G/A

Recent SEC filings of Corbus Pharmaceuticals Holdings

View All Filings
Date Filed Form Type Document
Aug 08, 2023
8-K
Current Report
Aug 08, 2023
10-Q
Quarterly Report
Aug 03, 2023
8-K
Current Report

Peers (Alternatives to Corbus Pharmaceuticals Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
269.9B
56.0B
3.85% 7.89%
31.08
4.82
-2.31% -31.27%
262.3B
1.8B
-6.03% 32.32%
-151.4
144.85
69.45% 14.65%
90.1B
9.5B
-0.31% 22.07%
26.78
9.48
13.83% 5.33%
88.3B
12.7B
-1.90% 19.84%
20.53
6.97
-10.94% -24.40%
21.4B
1.2B
-9.89% -15.37%
-20.15
17.32
39.94% -8.44%
11.2B
1.0B
4.78% 8.17%
-12.32
11.15
20.15% -79.16%
10.4B
2.1B
-3.76% 7.10%
11.99
4.95
18.01% 38.16%
MID-CAP
3.0B
225.6M
-0.48% -26.20%
-5.42
13.31
-2.11% 21.02%
2.8B
-
-14.43% 145.38%
-8.58
-
- -28.88%
2.6B
402.9M
-0.46% -15.55%
-3.61
6.46
20.50% -42.46%
2.4B
27.2M
9.19% -41.38%
-3.24
87.87
- -14.43%
SMALL-CAP
3.1B
-
-6.35% -39.96%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-14.43% -0.82%
11.15
4.25
77.72% 112.02%
288.6M
152.5M
-11.24% 54.82%
38.75
1.89
127.84% 103.41%
30.1M
-
1.72% 3677.78%
-0.65
-
- -31.51%

Corbus Pharmaceuticals Holdings News

MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day.
MarketWatch,
2 days ago
Insider Monkey
Seeking Alpha
Seeking Alpha

Returns for CRBP

Cumulative Returns on CRBP

1.2%


7-Year Cumulative Returns

-0.4%


5-Year Cumulative Returns

60.7%


3-Year Cumulative Returns

Risks for CRBP

What is the probability of a big loss on CRBP?

100%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 20% underwater in next one year

100%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 30% underwater in next one year.

89.2%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRBP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Corbus Pharmaceuticals Holdings was unfortunately bought at previous high price.

Drawdowns

Financials for Corbus Pharmaceuticals Holdings

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q12016Q4
Revenue-42.7%8821,5402,6732,8233,9375,8537,21236,02036,14435,49733,9985,7584,8222,8952,6002,0972,4402,8162,7622,8091,911
Operating Expenses-16.8%56,87168,34389,575111,162126,747135,041127,523116,487113,248103,00391,30577,16361,57052,91444,67839,07235,00332,089---
  S&GA Expenses-23.8%16,41721,55123,95526,12228,48029,39627,24924,71823,64321,10518,75116,53112,95611,79410,7439,6348,9648,957---
  R&D Expenses-33.6%31,06246,79265,61985,04098,267105,645100,27491,76989,60581,89872,55460,63248,61441,12033,93429,43826,03923,132---
Interest Expenses13.6%-1,830-2,119-2,181-1,767-1,028-1885595511,22830214.0011.0010.0010.0013.0013.0012.0012.00---
Net Income-3.7%-45,640-43,991-76,710-97,677-111,269-129,238-115,133-74,875-71,453-62,179-55,989-70,211-55,672-49,059-41,424-36,651-32,421-29,298---
Net Income Margin-81.2%-51.76*-28.57*-28.70*-29.55*-28.26*-8.83*-4.55*-2.08*-1.98*-1.75*-----------
Free Cashflow14.9%-48,237-56,653-84,820-93,914-100,170-105,851-96,822-86,772-48,463------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-15.3%44.0052.0066.0074.0082.0096.0010812012114010296.0098.0065.0049.0068.0084.0010147.0061.0070.00
  Current Assets-16.6%38.0046.0060.0067.0075.0088.0010011211213092.0085.0088.0055.0038.0058.0075.0093.0044.0058.0068.00
    Cash Equivalents14.0%8.007.0017.0012.0026.0057.0025.0037.0036.0067.0085.0082.0063.0047.0032.0055.0073.0090.0042.0056.0065.00
  Net PPE-11.1%1.001.002.002.002.002.002.003.004.004.004.004.005.005.005.005.003.003.003.003.003.00
Liabilities-2.8%34.0035.0033.0032.0033.0035.0039.0042.0044.0049.0057.0067.0050.0043.0043.0038.0037.0059.0019.0018.0015.00
  Current Liabilities14.1%16.0014.0013.0017.0016.0015.0017.0017.0019.0024.0032.0041.0042.0035.0035.0031.0029.0052.0018.0017.0013.00
    LT Debt, Non Current-19.0%11.0014.0016.009.0012.0014.0016.0019.0018.0018.0018.0018.00---------
Shareholder's Equity-42.2%10.0016.0033.0042.0049.0061.0069.0078.0077.0092.0045.0029.0048.0023.006.0030.0047.0042.0028.0043.0055.00
  Retained Earnings-2.1%-418-409-392-381-372-359-349-339-337-320-304-295-260-222-192-166-145-147-121-104-89.46
  Additional Paid-In Capital0.4%428426425423422420419417414412349325309245199196193190149147145
Shares Outstanding4.9%4.004.004.004.004.004.004.004.004.004.003.003.002.002.002.002.002.002.002.002.002.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations10.5%-37,615-42,044-37,544-39,792-31,690-36,989-48,183-56,705-84,815-93,894-99,685-104,023-93,856-83,640-45,720-37,223-28,983-18,149-30,067-25,116-22,601
  Share Based Compensation-13.4%4,4655,1545,7206,2447,4988,4929,48010,02811,06011,90112,45813,21412,56112,03011,98210,8349,8158,8147,6107,1216,513
Cashflow From Investing374.8%20,166-7,33830,07415,11721,37226,970-73,416-70,187-70,527-57,445-484-1,828-2,965-3,132-2,742-1,700-612-1,104-2,300-2,630-2,570
Cashflow From Financing108.9%28.00-319-5331*8.0083.0060,82381,790128,625172,355154,875133,89287,13643,47138,46338,11438,07438,21811,42046,61046,616

CRBP Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:    
Research and development$ 4,248,705$ 2,499,642$ 17,637,048$ 5,785,878
General and administrative3,940,2864,840,3687,848,96810,071,291
Litigation settlement05,000,00005,000,000
Total operating expenses8,188,99112,340,01025,486,01620,857,169
Operating loss(8,188,991)(12,340,010)(25,486,016)(20,857,169)
Other income (expense), net:    
Other income (expense), net182,657(208,683)412,164(402,034)
Interest income (expense), net(775,586)(490,339)(1,453,608)(949,248)
Foreign currency exchange gain (loss), net(1,921)(209,856)(1,193)(477,679)
Other expense, net594,850(908,878)(1,042,637)(1,828,961)
Net loss$ (8,783,841)$ (13,248,888)$ (26,528,653)$ (22,686,130)
Earnings Per Share, Basic$ (2.05)$ (3.18)$ (6.27)$ (5.44)
Earnings Per Share, Diluted$ 2.05$ (3.18)$ (6.27)$ (5.44)
Weighted Average Number of Shares Outstanding, Basic4,277,7014,170,4644,229,8944,170,255
Weighted Average Number of Shares Outstanding, Diluted4,277,7014,170,4644,229,8944,170,255
Comprehensive loss:    
Net loss$ (8,783,841)$ (13,248,888)$ (26,528,653)$ (22,686,130)
Other comprehensive income (loss):    
Change in unrealized gain (loss) on marketable debt securities44,68150,373102,304(56,875)
Total other comprehensive income (loss)44,68150,373102,304(56,875)
Total comprehensive loss$ (8,739,160)$ (13,198,515)$ (26,426,349)$ (22,743,005)

CRBP Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 8,349,346$ 17,002,715
Investments28,216,56042,194,296
Restricted cash192,475192,475
Prepaid expenses and other current assets1,515,616791,616
Total current assets38,273,99760,181,102
Restricted cash477,425477,425
Property and equipment, net1,273,6021,613,815
Operating lease right of use assets3,486,4163,884,252
Other assets211,943155,346
Total assets43,723,38366,311,940
Current liabilities:  
Notes payable51,157353,323
Accounts payable1,505,7342,173,963
Accrued expenses6,418,8035,999,252
Derivative liability36,86836,868
Operating lease liabilities, current1,357,2401,280,863
Current portion of long-term debt7,016,0962,795,669
Total current liabilities16,385,89812,639,938
Long-term debt, net of debt discount11,319,36515,984,426
License agreement payable, noncurrent2,500,0000
Other long-term liabilities22,20522,205
Operating lease liabilities, noncurrent3,975,3294,675,354
Total liabilities34,202,79733,321,923
Stockholders' equity  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no sharesissued and outstanding at June 30, 2023 and December 31, 2022. See Note 1100
Common stock, $0.0001 par value; 300,000,000 shares authorized,4,422,741 and 4,171,297 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively442417
Additional paid-in capital428,153,252425,196,359
Accumulated deficit(418,609,320)(392,080,667)
Accumulated other comprehensive loss(23,788)(126,092)
Total stockholders’ equity9,520,58632,990,017
Total liabilities and stockholders’ equity$ 43,723,383$ 66,311,940
Yuval Cohen
40
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.